Key Updates and Practice-Changing Data for Advanced NSCLC

EP. 1: The KEYNOTE-024 Precedent for Advanced-NSCLC Treatment

November 16th 2018

EP. 2: The KEYNOTE-042 and IMpower150 PD-L1 Treatments

November 16th 2018

EP. 3: IMpower131 & KEYNOTE-407/189 Squamous NSCLC Treatments

November 16th 2018

EP. 4: Immunotherapy Paradigm for Newly Diagnosed NSCLC

November 16th 2018

EP. 5: Second-line Treatment for Nondriver Metastatic NSCLC

November 16th 2018

EP. 6: Various Forms of Disease Progression in Advanced NSCLC

November 16th 2018

EP. 7: Pembrolizumab as Treatment for Oligometastatic NSCLC

November 16th 2018

EP. 8: Post-Immunotherapy & Frontline Treatments for Advanced NSCLC

November 16th 2018

EP. 9: I-O Options for Stage III NSCLC & International PD-L1 Restrictions

November 16th 2018

EP. 10: Surgery Options for NSCLC & I-O Therapy in EGFR-Mutations

November 16th 2018

EP. 11: Pembrolizumab Treatment in Stage III NSCLC and Alternatives

November 16th 2018

EP. 12: First-Line Shifts in Driver-Mutation Subsets According to FLAURA

November 16th 2018

EP. 13: Treatment Options for ALK/ROS1 Mutation

November 16th 2018

EP. 14: HER2- and MET-Mutation/Amplification Therapies

November 16th 2018

EP. 15: RET-Fusion NSCLC Treatments LOXO-292 & BLU-667

November 16th 2018

EP. 16: I-O as First-Line Therapy for Driver-Mutated NSCLC

November 16th 2018

EP. 17: The Current State of Advanced NSCLC Treatment & Contingencies

November 16th 2018

EP. 18: Immunotherapy Options for Lung Cancer Variations

November 16th 2018

EP. 19: Treatment Options for Lung Cancer Mutations & Contingencies

November 16th 2018

x